| 9.07 -1.17 (-11.43%) | 10-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.58 |
1-year : | 12.34 |
| Resists | First : | 9.91 |
Second : | 10.56 |
| Pivot price | 9.63 |
|||
| Supports | First : | 8.85 |
Second : | 7.37 |
| MAs | MA(5) : | 9.76 |
MA(20) : | 9.54 |
| MA(100) : | 9.99 |
MA(250) : | 11.95 |
|
| MACD | MACD : | 0 |
Signal : | 0  |
| %K %D | K(14,3) : | 60.4 |
D(3) : | 73.5 |
| RSI | RSI(14): 42.2 |
|||
| 52-week | High : | 16.98 | Low : | 8.5 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ OFIX ] has closed above bottom band by 6.1%. Bollinger Bands are 29% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 10.3 - 10.36 | 10.36 - 10.41 |
| Low: | 8.77 - 8.83 | 8.83 - 8.88 |
| Close: | 8.99 - 9.08 | 9.08 - 9.16 |
Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Germany, France, and the United Kingdom, as well as Brazil and other international markets. The company's operations are divided into two main segments: Global Spine and Global Orthopedics. Within the Global Spine division, Orthofix is responsible for the development, production, and distribution of bone growth stimulators. These devices are designed to facilitate bone fusion and serve as a therapeutic intervention for fractures located outside the spine and in the limbs. This segment also creates and commercializes a range of motion preservation and fixation implant products utilized in spinal surgical procedures. Furthermore, it supplies physicians with various tissue forms and synthetic-based regenerative biologic solutions to address a wide spectrum of spinal and orthopedic conditions. The Global Orthopedics segment concentrates on the design, development, and commercialization of specialized orthopedic products. These offerings are essential for procedures involving fracture repair, the correction of deformities, and bone reconstruction. Orthofix distributes its products to a diverse clientele, including physicians, hospitals, outpatient surgery centers, and integrated health delivery systems. This is achieved through a comprehensive sales network that includes its own sales force, independent distributors, and both employed and external sales representatives. The company, previously known as Orthofix International N.V., officially changed its name to Orthofix Medical Inc. in July 2018.
Sun, 25 Oct 2026
Orthofix Medical Inc. Estimates – NASDAQ:OFIX - TradingView
Fri, 23 Oct 2026
Orthofix to Report Third Quarter 2026 Financial Results - Business Wire
Mon, 28 Sep 2026
Juniper Investment Company, LLC Adds Orthofix Medical Inc (OFIX) -- Shares Look 30% Undervalued on GF Value - GuruFocus
Mon, 10 Aug 2026
CCORF Maintains Orthofix Medical(OFIX.US) With Buy Rating, Cuts Target Price to $13 - Moomoo
Thu, 06 Aug 2026
Orthofix Medical (OFIX) Stock Sinks As One Off Growth Clouds Outlook - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 40 (M) |
| Shares Float | 40 (M) |
| Held by Insiders | 2.1 (%) |
| Held by Institutions | 95.7 (%) |
| Shares Short | 2,440 (K) |
| Shares Short P.Month | 2,380 (K) |
| EPS | -1.52 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.53 |
| Profit Margin | -7.5 % |
| Operating Margin | -3.3 % |
| Return on Assets (ttm) | -2.8 % |
| Return on Equity (ttm) | -14 % |
| Qtrly Rev. Growth | 3.7 % |
| Gross Profit (p.s.) | 14.68 |
| Sales Per Share | 20.61 |
| EBITDA (p.s.) | 0.51 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 16 (M) |
| Levered Free Cash Flow | 4 (M) |
| PE Ratio | -5.97 |
| PEG Ratio | 48.8 |
| Price to Book value | 0.86 |
| Price to Sales | 0.44 |
| Price to Cash Flow | 22.53 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|